Cover Image
市場調查報告書

Lamivudine的中國市場分析

Investigation Report on China Lamivudine Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 334093
出版日期 內容資訊 英文 35 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Lamivudine的中國市場分析 Investigation Report on China Lamivudine Market, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 35 Pages
簡介

Lamivudine是B型肝炎病毒和HIV/AIDS的有力治療藥之一,中國政府免費提供給AIDS患者(無併發B型肝炎的情形)。北美各國在1990年代先通過AIDS治療藥的認証,1998年亦通過B型肝炎的認証。中國也在1999年通過為B型肝炎治療藥。之後中國的Lamivudine市場便一直急速成長到2012年但預測2013年成長率將減緩。

本報告提供中國的Lamivudine的市場相關分析,提供您整體市場規模趨勢(過去5年份)和國內價格趨勢,各企業·給藥型態別的市場佔有率,主要製造商簡介,未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 Lamivudine的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Lamivudine市場概況

  • 中國國內的Lamivudine的專利申請·認證情形
  • 主要製造商
  • 市場規模

第3章 Lamivudine銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Lamivudine市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (以銷售額為準)
  • 市場佔有率 (以銷售量為準)

第5章 中國的Lamivudine市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (以銷售額為準)
  • 各劑型的市場佔有率 (以銷售量為準)

第6章 Lamivudine的醫院用標準價格

  • Beijing Wansheng Pharmaceutical Co., Ltd (商標名:Wanshenglike)
  • Burroughs Wellcome & Company (英國) (商標名:Heptodin)
  • Anhui Biochem United Pharmaceutical Co., Ltd (商標名:Yinding)
  • Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd (商標名:Jianganling)
  • Fujian Cosunter Pharmaceutical Co., Ltd (商標名:Heganding)
  • GlaxoSmithKline Pharmaceuticals (Suzhou) Limited (商標名:Heptodin)

第7章 中國國內的Lamivudine的主要製造商 (過去5年份)

  • Anhui Biochem United Pharmaceutical Co., Ltd
  • Fujian Cosunter Pharmaceutical Co., Ltd
  • Beijing Wansheng Pharmaceutical Co., Ltd
  • GlaxoSmithKline Pharmaceuticals (Suzhou) Limited
  • Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd

第8章 中國的Lamivudine市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1507254

Acoording to the report issued by the Joint United Nations Programme on HIV and AIDS in 2014, by the end of 2013, patients with human immune deficiency virus/acquired immune deficiency syndrome (HIV/ AIDS) had amounted to 35 million and the number of new cases of HIV/AIDS had been 6000 a day on average. And by the end of 2011, patients with HIV/ AIDS in China was estimated to be 0.78 million, the number of new cases of HIV/AIDS was 48,000 and people die of diseases related with AIDS reached 28,000.

Lamivudine, an important drug for hepatitis B Virus (HBV) and AIDS, is one of the products regulated by the Chinese government to be provided to patients with AIDS (patients with hepatitis B not included) for free. As an antiviral nucleotide analog, lamivudine can competitively inhibit the synthesis and elongation of viral DNA chain. First used by some countries in Europe and North America for the treatment of AIDS in the early 1990s, lamivudine was approved by FDA to be used for the treatment of hepatitis B in 1998 after some medical experts discovered its inhibiting effect on HBV DNA in the middle 1990s. Lamivudine was approved by CFDA mainly as hepatitis B drug and began its sales in China in 1999.

Lamivudine develops fast after entering China with sales value reaching up to CNY 307 million in 2012 despite its gradual drop since 2013. GlaxoSmithKline Pharmaceuticals (Suzhou) Limited, Beijing Wansheng Pharmaceutical Co., Ltd, Burroughs Wellcome & Company (UK) and Fujian Cosunter Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among which GlaxoSmithKline Pharmaceuticals (Suzhou) Limited had the largest market share of about 72% for sales value in 2014.

With the large amounts of patients with hepatitis B and AIDS in China, the market size of lamivudine is expected to have growth potential.

Readers can get at least the following information from this report:

  • market size of lamivudine in China
  • competitive landscape of lamivudine in Chinese market
  • price of lamivudine made by different enterprises in China
  • market outlook of lamivudine in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-HBV drugs
  • manufacturers of anti-AIDS drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Lamivudine

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Lamivudine in China

  • 2.1. Patent and Approval Status of Lamivudine in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Lamivudine in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Lamivudine in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Lamivudine in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Lamivudine in Chinese Hospitals in 2014

  • 6.1. Beijing Wansheng Pharmaceutical Co., Ltd (Trade Name: Wanshenglike)
  • 6.2. Burroughs Wellcome & Company (UK) (Trade Name: Heptodin)
  • 6.3. Anhui Biochem United Pharmaceutical Co., Ltd (Trade Name: Yinding)
  • 6.4. Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd (Trade Name: Jianganling)
  • 6.5. Fujian Cosunter Pharmaceutical Co., Ltd (Trade Name: Heganding)
  • 6.6. GlaxoSmithKline Pharmaceuticals (Suzhou) Limited (Trade Name: Heptodin)

7. Major Manufacturers of Lamivudine in Chinese Market, 2010-2014

  • 7.1. Anhui Biochem United Pharmaceutical Co., Ltd
  • 7.2. Fujian Cosunter Pharmaceutical Co., Ltd
  • 7.3. Beijing Wansheng Pharmaceutical Co., Ltd
  • 7.4. GlaxoSmithKline Pharmaceuticals (Suzhou) Limited
  • 7.5. Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd

8. Market Outlook of Lamivudine in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Lamivudine in China
  • Chart Approval Information of Lamivudine in China
  • Chart Sales Status of Lamivudine in China
  • Chart Sales Value of Lamivudine in China, 2010-2014
  • Chart Sales Value of Lamivudine in Some Regions in China, 2010-2014
  • Chart Sales Volume of Lamivudine in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Lamivudine for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Made by GlaxoSmithKline Pharmaceuticals (Suzhou) Limited in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Made by Burroughs Wellcome & Company (UK) in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Made by Fujian Cosunter in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Capsules in China, 2010-2014
  • Chart Sales Volume and Market Share of Lamivudine Tablets in China, 2010-2014
  • Chart Sales Volume and Market Share of Lamivudine Capsules in China, 2010-2014
  • Chart Price of Lamivudine Made by Beijing Wansheng Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by Burroughs Wellcome & Company (UK) in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by Anhui Biochem United Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by Fujian Cosunter Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by GlaxoSmithKline Pharmaceuticals (Suzhou) Limited in Some Chinese Cities in 2014
Back to Top